Clinical Research Papers:

Increased risk of malignancy in patients with an aortic aneurysm: a nationwide population-based retrospective study

Jen-Chun Wang, Wu-Chien Chien, Chi-Hsiang Chung, Wen-I Liao, Chang-Huei Tsao, Yung-Fu Wu and Shih-Hung Tsai _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2018; 9:2829-2837. https://doi.org/10.18632/oncotarget.20181

Metrics: PDF 1278 views  |   HTML 2385 views  |   ?  


Jen-Chun Wang1,2, Wu-Chien Chien3,4,*, Chi-Hsiang Chung3,4,5, Wen-I Liao1, Chang-Huei Tsao3,6, Yung-Fu Wu3 and Shih-Hung Tsai1,*

1Department of Emergency Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

2Institute of Clinical Medicine, National Yang-Ming University, Taipei, Taiwan

3Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan

4School of Public Health, National Defense Medical Center, Taipei, Taiwan

5Taiwanese Injury Prevention and Safety Promotion Association, Taipei, Taiwan

6Department of Microbiology and Immunology, National Defense Medical Center, Taipei, Taiwan

*These authors contributed equally to this work

Correspondence to:

Shih-Hung Tsai, email: [email protected]

Wu-Chien Chien, email: [email protected]

Keywords: aortic aneurysm, malignancy, transforming growth factor-β, Marfan syndrome, fibrillin

Received: March 15, 2017     Accepted: August 06, 2017     Published: August 11, 2017


Background: Cardiovascular disease and malignancy have numerous similarities and possible interactions, as these diseases share several risk factors, epidemiological features and biological signaling pathways. Data regarding the risk of malignancy in patients with aortic aneurysm (AA) are scarce. We aimed to determine whether patients with AA have an increased risk of malignancy.

Materials and Methods: The data for the nationwide population-based retrospective cohort study described herein were obtained from the Taiwan National Health Insurance Research Database (NHIRD). We selected adult patients who had been newly diagnosed with AA and were followed up between 2000 and 2010. We excluded patients who had been diagnosed with AA and malignancy prior to the date of the AA diagnosis. The control cohort was selected from individuals who had no history of AA and was selected with 1:4 matching according to co-morbidities and medication history. The outcome was a diagnosis of malignancy and the cumulative incidence of AA.

Results: A total of 10,933 patients diagnosed with AA were identified. The patients with an AA had a significantly higher cumulative risk of developing malignancies in subsequent years than the patients without an AA (log rank test < 0.001). Similarly, patients with malignancies had a significantly higher cumulative risk of developing an AA in subsequent years than patients without malignancies (log rank test < 0.001).

Conclusions: Patients with an AA were shown to have a substantially increased risk of developing a variety of malignancies compared with patients without AAs. Healthcare professionals should be aware of this increased risk when treating patients with AAs.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 20181